Bod Australia is primarily a developer and distributor of cosmetics and natural medicines, with a significant distribution footprint in the Australian market.
In the past few months, Bod has recently completed a number of pivotal steps towards the commencement of its phase 1 trial, including trial site initiation, product formulation of the trial-ready product, patient recruitment and screening processes and gaining regulatory approvals from the Therapeutic Goods Administration (TGA).
From a commercial perspective, Bod has also been active in recent weeks. The company has also looked to expand its distribution network in order to boost sales nationwide
If its phase 1 clinical trial is successful, Bod will look to develop a unique, standardised, reproducible and patent protected cannabis product which can be sold domestically, internationally or licenced to large-scale pharmaceutical companies.
Following phase 1, Bod is then likely to move to phase 2 clinical trials sometime next year whereby its product will be evaluated for specific indications such as chemotherapy-associated nausea and vomiting, multiple sclerosis, epilepsy, anti-inflammation treatment and anxiety.
BDA Price at posting:
52.0¢ Sentiment: Buy Disclosure: Held
